KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Gross Margin (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Gross Margin for 12 consecutive years, with 99.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 241.0% year-over-year to 99.0%, compared with a TTM value of 97.89% through Dec 2025, up 121.0%, and an annual FY2025 reading of 97.89%, up 121.0% over the prior year.
  • Gross Margin was 99.0% for Q4 2025 at Travere Therapeutics, up from 96.04% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.32% in Q4 2021 and bottomed at 86.58% in Q1 2023.
  • Average Gross Margin over 5 years is 95.39%, with a median of 96.45% recorded in 2023.
  • The sharpest move saw Gross Margin crashed -717bps in 2023, then skyrocketed 978bps in 2024.
  • Year by year, Gross Margin stood at 99.32% in 2021, then dropped by -2bps to 97.04% in 2022, then decreased by -7bps to 89.87% in 2023, then rose by 7bps to 96.59% in 2024, then grew by 2bps to 99.0% in 2025.
  • Business Quant data shows Gross Margin for TVTX at 99.0% in Q4 2025, 96.04% in Q3 2025, and 98.67% in Q2 2025.